The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).
Robert John Motzer
No relevant relationships to disclose
Pankaj Bhargava
No relevant relationships to disclose
Brooke Esteves
No relevant relationships to disclose
Mohammed Al-Adhami
No relevant relationships to disclose
William Slichenmyer
No relevant relationships to disclose
Dmitry Nosov
No relevant relationships to disclose
Tim Eisen
No relevant relationships to disclose
Cora N. Sternberg
No relevant relationships to disclose
Thomas E. Hutson
No relevant relationships to disclose